These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 37375652)

  • 1. Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation.
    Novi S; Vestuto V; Campiglia P; Tecce N; Bertamino A; Tecce MF
    Nutrients; 2023 Jun; 15(12):. PubMed ID: 37375652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.
    Malnick SDH; Alin P; Somin M; Neuman MG
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
    Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
    World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells.
    Goonetilleke M; Kuk N; Correia J; Hodge A; Moore G; Gantier MP; Yeoh G; Sievert W; Lim R
    Stem Cell Res Ther; 2021 Jul; 12(1):429. PubMed ID: 34321089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human germline hedgehog pathway mutations predispose to fatty liver.
    Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
    J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.
    Hyun JY; Kim SK; Yoon SJ; Lee SB; Jeong JJ; Gupta H; Sharma SP; Oh KK; Won SM; Kwon GH; Cha MG; Kim DJ; Ganesan R; Suk KT
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
    Aljobaily N; Krutsinger K; Viereckl MJ; Joly R; Menlove B; Cone B; Suppes A; Han Y
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH.
    Fredrickson G; Barrow F; Dietsche K; Parthiban P; Khan S; Robert S; Demirchian M; Rhoades H; Wang H; Adeyi O; Revelo XS
    Mol Metab; 2021 Nov; 53():101270. PubMed ID: 34118476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH.
    Pompili S; Vetuschi A; Gaudio E; Tessitore A; Capelli R; Alesse E; Latella G; Sferra R; Onori P
    Nutrition; 2020; 75-76():110782. PubMed ID: 32268264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.